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Abstract
Background:  Back pain is a major health problem and many sufferers develop persistent
symptoms. Detecting relevant subgroups of patients with non-specific low back pain has been
highlighted as a priority area for research, as this could enable better secondary prevention through
the targeting of prognostic indicators for persistent, disabling symptoms. We plan to conduct a
randomised controlled trial to establish whether subgrouping using a novel tool, combined with
targeted treatment, is better than best current care at reducing long-term disability from low back
pain.
Methods/Design: We will recruit 800 participants aged 18 years and over with non-specific low
back pain from 8–10 GP practices within two Primary Care Trusts in Staffordshire, England. Our
primary outcome measures are low back pain disability and catastrophising. Secondary outcomes
include back pain intensity, global change, leg pain, fear avoidance, anxiety, depression, illness
perceptions, patient satisfaction, overall health status and cost-effectiveness. Data will be collected
before randomisation, and 4 and 12 months later. Participants are randomised to receive either
newly developed interventions, delivered by trained physiotherapists and targeted according to
subgroups defined by tool scores, or best current care.
Discussion: This paper presents detail on the rationale, design, methods and operational aspects
of the trial.
Trial registration: Current Controlled Trials ISRCTN37113406.
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Background
Back pain is a major health problem in the UK. Each year,
approximately 3.5 million people develop back pain [1],
and 7–9% of adults consult their GP.[2] Although most
sufferers stop consulting their GP within 3 months, 60–
80% still have pain or disability a year later.[3,4] Persist-
ent back pain affects peoples' quality of life, their family
and social relationships, and impairs their ability to
work.[5] Consequently, back pain has a huge economic
impact. [6-8]
Evidence for Treating Low Back Pain in Primary Care
Primary care guidelines for managing low back pain (LBP)
[9-11] have been developed within a biopsychosocial
framework which recognises that pain is influenced by
both tissue pathology and psychological factors, as well as
the social context in which the pain occurs. An estimated
85% of LBP consulters will have non-specific LBP, for
which diagnostic labelling is discouraged, and treatment
depends on the health care providers' preferences and
clinical experience.[12] The fundamental question of
"who will do best with which treatment" remains unan-
swered despite a number of high quality primary care-
based randomised trials of treatment options for LBP in
the last 2 years. [13-18]
Subgrouping and Targeted Treatment for Low Back Pain
Findings from primary care studies contrast with specialist
settings, where there is randomised controlled trial evi-
dence that cognitive behavioural approaches help selected
groups of patients with chronic back pain. [19,20] The
problem, therefore might be that treatments are not reach-
ing appropriate patient groups, and their effect is diluted
by the inclusion of heterogeneous patient populations.
Researchers are now questioning the appropriateness of
considering non-specific back pain patients to be a
homogenous group [21,22], and ways of identifying sub-
groups of patients who might benefit from specific thera-
pies has been recommended.[23] There is growing
evidence that psychosocial factors are particularly useful
for predicting individuals who will develop chronic back
pain, but in primary care these are difficult to spot and
often go unrecognised.[17,24] Even when primary care
clinicians do recognise psychosocial influences, they may
be unable to manage them effectively (without additional
training).[25] Researchers in some settings have devel-
oped clinical prediction rules to identify patients who are
more likely to respond to specific treatments.[26,27]
Other groups have developed and validated screening
tools that identify patients at risk of work absence.[21,28]
Early indications show these approaches to be promising,
with improved outcomes when subgrouping is used to
guide treatment decision-making.[29] Although it is rec-
ognised that these types of studies may improve the man-
agement of back pain patients, the implementation of
such systems remains unclear, and research on the identi-
fication and treatment of subgroups of patients is high-
lighted as the "main challenge" for the treatment of
LBP.[23]
Development of the Subgrouping Tool
In response to this challenge, a simple-to-use LBP sub-
grouping tool for use in primary care – the STarT Back
Tool – has been developed. [30-32] This tool classifies
patients into 3 categories for targeted treatment, based on
the presence of potentially modifiable physical and psy-
chological prognostic indicators for persistent, disabling
symptoms, identified through 9 questions. Patients are
classified as "low risk" of future disabling LBP if they score
positively on fewer than 4 questions. The remainder are
then subdivided into "medium risk" (physical and psy-
chosocial indicators for poor outcome, but without high
levels of psychological indicators) and "high risk" (high
levels of psychological prognostic indicators with or with-
out physical indicators).
Development of the Targeted Treatment Interventions
Alongside the development of the STarT Back tool, we
have developed targeted treatments for patients allocated
to the low, medium and high-risk subgroups; these have
been designed to address the specific modifiable prognos-
tic indicators identified by the tool. Evidence-based
assessment and treatment approaches for LBP patients
have been agreed and follow a "stepped-care" format. The
focus of the interventions is directed towards the second-
ary prevention of disabling back pain. A three-month
pilot study completed in September 2006 demonstrated
that the study methods were feasible and acceptable in a
LBP primary care population consulting their GP and
seeking treatment. They also showed that it is feasible to
recruit and treat the numbers of patients required for the
trial within the set timeframe.
Trial Objectives
The primary objective of this Trial is to compare the over-
all effectiveness of a "subgrouping for targeted treatment"
approach with "best current care" (non-targeted) physio-
therapy practice, over a 12 month period, for LBP. The tar-
geted treatments are delivered by specially trained
community physiotherapists.
Secondary objectives are: a) to investigate the change in
prognostic indicators separately for each subgroup (high,
medium and low risk) in the "targeted treatment" arm
compared with the change in the corresponding subgroup
in controls receiving "best current care" (non-targeted)
physiotherapy practice; and b) To evaluate the cost effec-
tiveness of the new model of care compared with "best
current care".BMC Musculoskeletal Disorders 2008, 9:58 http://www.biomedcentral.com/1471-2474/9/58
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Methods
Setting
Participants will be recruited from 8–10 general practices
within the Keele GP Research Partnership. This Partner-
ship includes a network of 30 practices that are committed
to high quality consultation recording using Read
Codes.[33] The population in this locality is primarily
urban with some rural and inner city areas, and is there-
fore broadly representative of the population in the UK.
Community Back Pain Clinics, through which patients
can be recruited to the Trial, are held at two Primary Care
Centres within this locality.
Ethical approval
Ethical approval was obtained from the North Stafford-
shire Local Research Ethics Committee in February 2007
(ref number 07/Q2604/5).
Eligibility criteria
Male and female subjects aged 18 years and above who
seek care for LBP with or without associated leg pain are
eligible to take part. Participants must speak and under-
stand English and be willing and able to give full,
informed written consent. The exclusion criteria are:
potentially serious pathology (e.g. cauda equina compres-
sion, inflammatory arthritis, malignancy etc), serious co-
morbidity, psychiatric illness or personality disorder; spi-
nal surgery in the last 6 months; pregnancy; already receiv-
ing treatment other than GP care for this episode of back
pain; and inability to attend regular physiotherapy
appointments.
Recruitment
Participants are identified when they consult their GP,
practice nurse or the local Physiotherapy Direct Access
service (Physio Direct) for LBP. At the GP practices, previ-
ously validated back pain Read Codes will be used to
identify patients.[2] When a clinician enters one of these
Read Codes, a pop up screen will remind them that the
patient will be invited to a Community Back Pain Clinic.
At this point the clinician can choose to "opt out" if the
patient is considered to be inappropriate for referral to the
Clinic, and/or is ineligible to take part in the Trial. The
remaining patients are given an information sheet about
the Clinic. One participating GP practice uses the local
"Physio Direct" service, which offers direct access for
patients with back pain, without the need for an initial
consultation with their GP. Patients from this GP Practice
who telephone the Physio Direct service instead of con-
sulting their GP are initially assessed over the phone by a
physiotherapist. Potentially eligible patients will be told
about the Community Back Pain Clinic by the assessing
physiotherapist and sent a clinic information sheet. All
patients identified from the GP practices and Physio
Direct are mailed a letter inviting them to telephone for an
appointment at the Community Back Pain Clinic, along
with a patient information leaflet about the Trial and a
baseline questionnaire. Patients who telephone are given
an appointment at one of the Community Back Pain Clin-
ics. At the clinic, patients see a research nurse who
explains the Trial in detail. For those patients interested in
taking part, the nurse then goes through the written
informed consent process. The research nurse is blinded
to the patient's treatment allocation throughout the trial.
All patients are assessed by an experienced physiothera-
pist at the clinic, regardless of whether they choose to take
part in the Trial or not.
Baseline assessment
All patients invited to the Community Back Pain Clinic
are requested to complete the postal questionnaire and
those who consent to take part in the study complete a
further self report questionnaire in clinic. The question-
naires include the STarT Back Tool [32], age, gender, edu-
cational attainment and the outcome measures listed in
Table 2 at time point zero.
Treatment allocation
Following completion of the baseline questionnaire,
patients who consent to take part in the Trial are ran-
domly allocated to one of the two treatment arms: "tar-
geted treatment" or "best current care" (see Figure 1). After
calculating the patient's STarT Back tool score from the
postal questionnaire, the clinic administrator telephones
the Primary Care Musculoskeletal Research Centre ran-
domisation service.[15,34] Patients are randomised using
a stratified block randomisation method according to
Centre and risk subgroup. Random allocation is on a 2:1
(targeted treatment: best current care) ratio basis with a
block size of three. This gives three possible permutations
of treatment allocation per block: AAB; ABA; BAA. The
research nurse in clinic is blinded to a patient's treatment
allocation.
Interventions
1) Targeted Treatment
All patients randomised to 'targeted treatment' receive an
initial 30-minute protocolised intervention with a spe-
cially trained study physiotherapist. Patients receive reas-
surance about the benign nature of their pain, and simple
messages of advice around issues such as pain relief,
appropriate activity levels and the role of further investi-
gations. The physiotherapist is guided by the results of the
patient's STarT Back tool score so that specific concerns
can be identified and addressed on an individual basis. To
reinforce key messages the 'Back Book' [35] is given,
together with an information sheet of local contacts for
exercise venues such as swimming pools, gyms and exer-
cise on prescription, and self-help groups. A 15-minute
educational video based on The Back Book, called 'GetBMC Musculoskeletal Disorders 2008, 9:58 http://www.biomedcentral.com/1471-2474/9/58
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STarT Back Trial Flow Chart Figure 1
STarT Back Trial Flow Chart.
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Back Active' [36] is shown to patients to reinforce key mes-
sages. Patients allocated to the 'low risk' group receive no
further treatment in addition to this 30 minute clinic
appointment.
For patients allocated to receive the medium and high risk
subgroup interventions, the study administrator arranges
further appointments with specially trained physiothera-
pists within two weeks of their clinic date. Treatments for
the medium and high risk groups were developed after
reviewing available literature and guidelines to identify
best practice treatment, and are delivered during a target
time of six weeks. The focus was to provide secondary pre-
vention of disabling back pain through the provision of
treatment targeted at the specific modifiable prognostic
indicators identified by the STarT Back tool (see below).
Patients in the 'medium risk' group present with predom-
inantly physical prognostic indicators (disabling back
pain, referred leg pain and co-morbid pain), without high
levels of psychosocial distress. The 'medium risk' group
package of care therefore, targets physical characteristics
using a range of physiotherapy techniques delivered over
6, 30-minute sessions. Management includes an assess-
ment and differential diagnosis (particularly for patients
with referred leg pain), and treatment designed to reduce
disability related to future episodes of low back pain.
The 'high risk' group physiotherapy treatment is tailored
for patients who present with high psychosocial indica-
tors such as anxiety and fear. Therapists are given extra
training to deliver this package, which helps them identify
and address pain related psychological distress through
the use of appropriate cognitive behavioural strategies.
Goal setting, where realistic treatment goals are negotiated
with patients using a Goal Attainment Scale.[37] The
components of the targeted treatments are outlined in
Table 1.
2) Best Current Care
Patients randomised to the control arm have a 30-minute
consultation with an experienced community physiother-
apist (not involved in the 'targeted treatment' arm) who is
blinded to the results of the STarT Back tool. A manage-
ment plan is formulated according to normal clinical
practice. This may include referral to community physio-
therapy if thought necessary.
Patients from both "targeted treatment" and "best current
care" arms are advised that they can access their GP for
ongoing care in the usual way, and that they should con-
tact their GP if their condition worsens.
Audit of interventions
At the clinic, both study physiotherapists and community
physiotherapists complete case report forms for all
patients participating in the trial. This records assessment
findings relating to leg pain and documents medication
and advice given in clinic. Physiotherapists who deliver
the targeted treatment use a standard proforma to record
the number of treatment sessions each participant
receives, plus details about the treatments delivered at
each session. They also receive regular clinical mentoring
and supervision sessions with expert members of the
STarT Back Trial team who are responsible for training.
Outcome measures
As the main focus of this trial is secondary prevention of
chronic back pain, primary clinical outcomes are changes
in the main physical and psychosocial risk factors for
chronicity: disability (Roland-Morris Disability Question-
naire (RMDQ)) [38] and pain catastrophising (Pain Cata-
strophising Scale) [39] (see Table 2). The RMDQ is a
recommended disability measure [40] that it is widely
used in low back pain studies in Primary Care, and pain
catastrophising has been shown to be an important pre-
dictor of quality of life.[41]
Table 1: Components of Targeted Treatment
Low, medium and high risk groups (30-minute structured intervention)
• Evidence-based assessment of LBP presentations, according to current guidelines.
• Advice on back care emphasising positive messages about activity, pain relief and work.
• Patients are given a copy of "The Back Book" [35] and see a 15-minute video based on The Back Book entitled "Get Back Active" [36].
Medium and high risk groups
• Treatment according to STarT Back assessment and treatment algorithms and STarT Back physiotherapy manual.
• Evidence-based physiotherapy techniques addressing 'signs and symptoms' in non-specific LBP presentations, according to current 
recommendations from guidelines and high quality clinical trials.
• Evidence-based advice, education and reassurance for symptoms and management, according to guidelines and current literature within the 
biopsychosocial model.
High risk group
• Assessing and addressing biopsychosocial risk factors by adopting cognitive behavioural principles to address unhelpful beliefs and behaviours.BMC Musculoskeletal Disorders 2008, 9:58 http://www.biomedcentral.com/1471-2474/9/58
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Secondary outcome measures are described in Table 2.
These were selected to fulfil recommendations on out-
come data [40], and to capture more fully some aspects of
back-related leg pain, psychological measures and quality
of life. [42-47] The health economic evaluation will con-
sist of a cost-utility analysis, with utility measured by the
EuroQol EQ-5D.[47] To estimate the costs of the study
interventions and consider the resource implications for
the targeted treatment approach, the 12-month self-report
questionnaire will collect resource use data for back pain-
specific and generic health care (direct costs) and details
of patients work absence due to low back pain (indirect
costs). All resources will be costed using UK national aver-
ages from freely available sources. [48-51]
Sample size
The primary outcome measure for this trial is the Roland
and Morris Disability Questionnaire (RMDQ) at 12-
months. A difference of 2.5 points in RMDQ change
scores is considered to be a minimum clinically important
difference in the RMDQ.[52] Our sample size calculation
is based on two separate hypothesis tests: (i) to test supe-
riority of targeted treatment over best current care for high
and medium risk subgroups; (ii) to test non-inferiority of
the targeted treatment compared to best current care in
the low risk subgroup. For the first hypothesis, a subgroup
sample size of 160 patients (107 and 53 per arm based on
a 2:1 allocation ratio) would enable detection of a
between-group difference of 2.5 RMDQ points given 80–
90% power, 5% (two-tailed) significance level, and a con-
servative standard deviation of 5 points. For the second
hypothesis, the targeted treatment will be concluded as
being non-inferior to best current care if the lower bound-
ary of the 95% confidence interval for the difference in
mean scores for targeted treatment minus best current care
(among low-risk participants) is above the threshold of -
Table 2: Outcome Measures
Domain Measures Time Point (months)
Primary Pain and disability Roland and Morris Disability Questionnaire [38] 0, 4, 12
Catastrophising Pain Catastrophising Scale [39] 0, 4, 12
Secondary Back Pain Pain intensity: 0–10 numerical rating scales of least & average pain in 
last 2 wks & current pain
0, 4, 12
Duration – time since month back pain free [42] 0
Back-related Leg symptoms -Leg pain in last week 0, 4, 12
-Location of leg pain 0, 4, 12
-Description of pain 0, 4, 12
-Presence of Numbness/parasthesia 0, 4, 12
Pain elsewhere Self complete manikin for bodily pain in last 4 weeks [43] 0, 12
Global change Compared to symptoms at baseline 4, 12
Kinesiophobia Tampa Scale Kinesiophobia [44] 0, 4, 12
Illness perceptions Musculoskeletal Illness Perceptions Questionnaire (MUSC-IPQ(R))† 0, 4, 12
Anxiety/depression Hospital Anxiety and Depression Scale [45] 0, 4, 12
Health-related quality of life Short Form 12 (version 2) [46] 0, 4, 12
Patient satisfaction -With current symptoms 0, 4
-With information received 4
-With care received 4
-With back pain knowledge 4
-Would have same treatment again 4
-Rating of overall results of care 4
Patient expectations -Expectations for LBP status 0
-Extent to which expectations were met 4
Employment details -Current employment status 0, 12
-Satisfaction with employment 0, 12
-Current/most recent job title 0, 12
-Work loss due back problem 0, 12
-Work loss due to other health problems 0, 4, 12
-Work performance 0, 12
Health care -Primary care consultations 4, 12
resource use -Secondary care attendances (NHS and private) 4, 12
-Additional health care practitioners (NHS and private) 12
-Prescription and over-the-counter medicines and treatments 12
Preference-based measure of 
health-related quality of life
EQ-5D [47] 0, 4, 12
† Instrument in development, Personal Communication, Nadine Foster.BMC Musculoskeletal Disorders 2008, 9:58 http://www.biomedcentral.com/1471-2474/9/58
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2.5 points (equivalent to a one-sided test with significance
level of 2.5%); 160 patients (107 and 53 per arm) allo-
cated on a 2:1 basis would be able to demonstrate non-
inferiority with 80–90% power. Pilot study data estimated
that 25%, 50% and 25% of participants would be in the
high, medium and low risk subgroups, respectively. These
figures were used to extrapolate the total sample size
requirement of 640 patients (160 in the high and low risk
subgroups and 320 in the middle risk subgroup), which
would ensure that we would have at least 80% power for
carrying out all three subgroup analyses. 800 participants
would need to be recruited to allow for a conservative
20% loss to follow up. Based on a 2:1 random allocation
basis, we would therefore expect about 533 and 267 to be
recruited to the "targeted treatment" and "best current
care" arms, respectively.
Data analysis
The primary analysis will be by intention to treat; a per
protocol analysis will be performed as a sensitivity analy-
sis. Estimates of treatment effects with 95% confidence
intervals ("targeted treatment" minus "best current care")
will be calculated. Statistical tests (analysis of covariance
(ANCOVA) for numerical outcomes; logistic regression
for categorical outcomes) will be performed adjusted for
imbalances in the baseline scores. Analyses will be carried
out at each time point (4 and 12 months) for primary and
secondary outcome measures; the primary endpoint is 12-
month follow up. Analyses will be carried out to compare
outcomes in patients randomised to "targeted treatment"
or "best current care" separately for each of the three sub-
groups (high, medium and low risk) of patients classified
according to the subgrouping tool.
An incremental approach will be used in the economic
evaluation. The primary aim is to estimate and compare
the societal costs associated with the study interventions
and relate this to the difference in the number of quality-
adjusted life years (QALYs). QALYs will be calculated by
applying area-under-the-curve techniques to the EQ-5D
scores at baseline, 4 months and 12 months.[53] Differ-
ences in costs and QALYs will be expressed using the
incremental cost-per-QALY ratio, with uncertainty
addressed using bootstrapping techniques, cost-effective-
ness planes and acceptability curves.[54,55] The robust-
ness of the results will be tested by conducting a number
of sensitivity analyses; namely, the consideration of alter-
native perspectives (e.g. adopting an NHS perspective),
the effect of incorporating 'generic' health care resource
use and the application of multiple imputation tech-
niques to deal with missing data.
An independent data monitoring committee will monitor
the trial every 6 months. There will be no interim analyses.
Conclusion
The STarT Back Trial will investigate the clinical and cost
effectiveness of a novel subgrouping and targeted treat-
ment approach for patients with non-specific low back
pain in Primary Care. Using the results of the Pilot study,
we estimate that we can recruit 800 patients to the trial in
12–18 months if we involve 8–10 GP practices from the
Keele GP Research Partnership and Physio Direct and run
3 Community Back Pain Clinics a week. Trial recruitment
commenced in July 2007 and is currently on target to
close before January 2009. Follow up is targeted for com-
pletion by February 2010 and results should be finalised
for publication in summer 2010.
The primary objective of the trial is to compare the clinical
outcomes of subgrouping and targeted treatment with
best current care over a 12 month period. The secondary
objectives are to compare the clinical outcomes for each of
the three subgroups compared with best current care over
12 months; and to evaluate the cost effectiveness of sub-
grouping and targeted treatment compared with best cur-
rent care at 12 months.
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